title: Intact parathyroid hormone concentration and cyclic AMP metabolism in thyroid disease.
abstract: In 35 thyrotoxic patients and 35 patients receiving thyroxine replacement therapy mean serum intact parathyroid hormone concentrations were lower than in euthyroid normal volunteer controls. In 20 hypothyroid patients intact PTH was increased relative to euthyroid controls. Mean serum adjusted calcium was increased in thyrotoxic patients relative to euthyroid controls and in 8 toxic patients with elevated serum adjusted calcium (greater than 2.60 mmol/l) intact PTH was below the assay detection limit (less than 0.5 pmol/l). Indices of PTH activity were consistent with intact PTH measurements in thyrotoxic patients with nephrogenous cyclic adenosine monophosphate lower, tubular maximum reabsorption of phosphate higher, and urinary calcium creatinine ratio higher than controls. In hypothyroid patients these indices of PTH activity suggest relative end organ resistance to PTH with nephrogenous cyclic adenosine monophosphate similar, tubular maximum reabsorption of phosphate similar, and calcium creatinine ratio lower than in controls. In treated hypothyroid patients nephrogenous cyclic adenosine monophosphate was higher, tubular maximum reabsorption of phosphate similar, and calcium creatinine ratio higher than in controls. These results are compatible with the hypothesis that thyroid status modifies the renal responses to PTH (1-84).
authors.affiliation: Institute of Biochemistry, Royal Infirmary Glasgow, Scotland.
authors.forename: W D
authors.initials: WD
authors.lastname: Fraser
authors.forename: F C
authors.initials: FC
authors.lastname: Logue
authors.forename: K
authors.initials: K
authors.lastname: MacRitchie
authors.forename: R M
authors.initials: RM
authors.lastname: Wilson
authors.forename: H W
authors.initials: HW
authors.lastname: Gray
authors.forename: G H
authors.initials: GH
authors.lastname: Beastall
authors.forename: D S
authors.initials: DS
authors.lastname: O'Reilly
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002118:Calcium / Q000378:metabolism; D003404:Creatinine / Q000378:metabolism; D000242:Cyclic AMP / Q000097:blood / Q000378:metabolism* / Q000652:urine; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000378:metabolism*; D007037:Hypothyroidism / Q000188:drug therapy / Q000378:metabolism*; D007684:Kidney Tubules / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood*; D010710:Phosphates / Q000378:metabolism; D012016:Reference Values; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood / Q000627:therapeutic use; D014284:Triiodothyronine / Q000097:blood
chemical_list: D010281:Parathyroid Hormone; D010710:Phosphates; D014284:Triiodothyronine; D013972:Thyrotropin; D003404:Creatinine; D000242:Cyclic AMP; D013974:Thyroxine; D002118:Calcium